IncobotulinumtoxinA (Xeomin)

Xeomin (incobotulinumtoxinA) is authorized only for the FDA‑approved adult indications—upper limb spasticity, cervical dystonia, blepharospasm in adults previously treated with onabotulinumtoxinA (Botox®), and chronic sialorrhea—and is not covered for patients <18, off‑label uses, active injection‑site infection, or known hypersensitivity to botulinum neurotoxin type A. Approvals are for 12 months with specified dosing/frequency limits (e.g., blepharospasm ≤35 units/eye q12 weeks; cervical dystonia 120 units q12 weeks; chronic sialorrhea 100 units q16 weeks; upper‑limb per‑muscle dosing q12 weeks), and require documentation of diagnosis, age, absence of infection/hypersensitivity, records of planned/administered dose, and for blepharospasm documented prior Botox® treatment (or provider rationale if prior dose is unknown).

"Upper limb spasticity in adults"

Sign up to see full coverage criteria, indications, and limitations.